Managed Healthcare Executive June 3, 2024
mRESVIA will be available for the 2024/2025 RSV season as a pre-filled, ready to use syringe.
The FDA has approved Moderna’s mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation.
RSV is a common virus that can lead to potentially serious respiratory illness. Older adults, including those with underlying medical conditions such as diabetes and chronic heart and lung disease, are at increased risk of severe RSV illness and drive the majority of RSV hospitalizations. About 177,000 adults 65 years and older are hospitalized in the United States because of RSV.
mRESVIA consists of...
Today's Sponsors
Today's Sponsor